文献速递临床试验与 GCP流行病学与生物统计

泼尼松龙与秋水仙碱治疗初级保健中急性痛风(COPAGO):双臂、多中心、实用性、前瞻性、随机、双盲、对照临床非劣效性试验方案,采用平行组设计

Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel group design.
PubMed 文献 · Trials · 2023-10-05

该方案计划在3个大学站点60家全科诊所开展实用性、前瞻性、双盲、双模拟、平行组、随机、非劣效性试验,比较泼尼松龙与秋水仙碱治疗急性痛风。干预组泼尼松龙30 mg用5天,对照组低剂量秋水仙碱(第1天1.5 mg;第2-5天1 mg)。主要结局为第3天最严重疼痛绝对水平(11项数字评定量表)。

要点

  • 泼尼松龙组30 mg用5天,秋水仙碱组第1天1.5 mg、第2-5天1 mg。
  • 主要结局为第3天过去24小时最严重疼痛的绝对水平,用11项数字评定量表测量。
  • 试验在3个大学站点60家全科诊所开展,纳入就诊于全科医生的成人急性痛风患者。

核心结论

  • 该试验将为初级保健中急性痛风使用秋水仙碱和泼尼松龙的疼痛缓解效果与副作用提供证据。

研究设计与样本

  • 实用性、前瞻性、双盲、双模拟、平行组、随机、非劣效性试验。
  • 在3个大学站点(格赖夫斯瓦尔德、哥廷根、维尔茨堡)的60家全科诊所开展。
  • 纳入就诊于全科医生的成人急性痛风患者。
  • 干预组接受泼尼松龙30 mg用5天;对照组接受低剂量秋水仙碱(第1天1.5 mg;第2-5天1 mg)。
  • 第0天为患者首次服用研究药物的日期,此后每日同一时间填写研究日记进行疼痛量化。

主要发现

  • 主要结局为第3天过去24小时最严重疼痛的绝对水平,用11项数字评定量表测量。
  • 次要结局包括平均治疗反应、肿胀、压痛和关节躯体功能、患者对治疗成功的整体评估、额外止痛药使用及非药物止痛治疗。
  • 出于安全原因,评估潜在副作用和收缩压变化过程。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验注册为回顾性注册(retrospectively registered)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gout is the most common form of rheumatic disease in which monosodium urate crystals are deposited in the joints followed by acute inflammatory reactions. There are various approved drugs that can be prescribed for pain relief during an acute gout attack. However, to date, no direct comparison of efficacy of colchicine and prednisolone for the treatment of acute gout attacks has been investigated. Furthermore, the majority of previous research studies were not only conducted in tertiary centres but also excluded patients with common comorbidities due to contraindications to naproxen. METHODS: This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial investigates whether prednisolone (intervention) is non-inferior to treatment with colchicine (active control) in patients with acute gout. Adult patients presenting with acute gout to their general practitioners in 60 practices across 3 university sites (Greifswald, Göttingen, and Würzburg) are eligible to participate in the study. Participants in the intervention group receive 30 mg prednisolone for 5 days. Those in the control group receive low-dose colchicine (day 1: 1.5 mg; days 2-5: 1 mg). The primary outcome is the absolute level of the most severe pain on day 3 (in the last 24 h) measured with an 11-item numerical rating scale. Day 0 is the day patients take their study medication for the first time. They are then asked to fill out a study diary the same time each day for pain quantification. Pain scores are used for comparison between the two medications. Secondary outcomes are average response to treatment, swelling, tenderness and physical function of the joint, patients' global assessment of treatment success, use of additional pain medication and non-pharmacological pain therapies. For safety reasons, potential side effects and course of systolic blood pressure are assessed. DISCUSSION: This trial will provide evidence on the effectiveness of pain reduction and side effects of colchicine and prednisolone in acute gout in primary care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05698680 first posted on January 26, 2023 (retrospectively registered). URL of trial registry record: https://clinicaltrials.gov/study/NCT05698680.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Truthmann J, Freyer Martins Pereira J, Richter A, et al. Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel group design. Trials. 2023. PMID: 37798801. doi:10.1186/s13063-023-07666-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。